Wednesday, October 23, 2024 OVC2 primary publication: Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005Lee J-M, Brady MF, Miller A, Moore RG, MacKay H, McNally L, Lea J, Street D, Lheureux S, McDonald ME, Duska LR, Cantuaria G, Kavecansky J, Leath CA, Powell M, Cadungog MG, Rose PG, Kim Y-M, Huang HQ, Provencher M, Wenzel LB, Bookman MA, Kohn EC, Alvarez Secord A. Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005 (ONLINE). Journal of Clinical Oncology 2024. https://ascopubs.org/doi/abs/10.1200/JCO.24.00683 GA3 primary publication: INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric CancerPavlakis N, Shitara K, Sjoquist K, Martin A, Jaworski A, Tebbutt N, Bang Y-J, Alcindor T, O'Callaghan C, Strickland A, Young Rha S, Lee K-W, Kim J-S, Bai L-Y, Hara H, Oh D-Y, Yip S, Zalcberg J, Price T, Simes J, Goldstein D. INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer (ONLINE). Journal of Clinical Oncology 2024. https://ascopubs.org/doi/abs/10.1200/JCO.24.00055 BLC1 primary publication: Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder CancerLerner SP, Tangen C, Svatek RS, Daneshmand S, Pohar KS, Skinner E, Schuckman A, Sagalowsky AI, Smith N, Kamat A, Kassouf W, Plets M, Bangs R, Koppie TM, Alva A, La Rosa FG, Pal SK, Kibel AS, Canter DJ, Thompson IM. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. New England Journal of Medicine 391: 1206-1216. 2024. https://www.nejm.org/doi/full/10.1056/NEJMoa2401497
